S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48

Akari Therapeutics Stock Forecast, Price & News

+0.01 (+0.70%)
(As of 01/19/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
121,342 shs
Average Volume
122,740 shs
Market Capitalization
$74.23 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Akari Therapeutics logo

About Akari Therapeutics

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$0.24 per share


Net Income
$-17.08 million
Pretax Margin




Free Float
Market Cap
$74.23 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.27 out of 5 stars

Medical Sector

1180th out of 1,415 stocks

Pharmaceutical Preparations Industry

568th out of 682 stocks

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Akari Therapeutics (NASDAQ:AKTX) Frequently Asked Questions

How has Akari Therapeutics' stock price been impacted by Coronavirus?

Akari Therapeutics' stock was trading at $1.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AKTX shares have decreased by 7.1% and is now trading at $1.43.
View which stocks have been most impacted by COVID-19

Are investors shorting Akari Therapeutics?

Akari Therapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 144,500 shares, an increase of 113.4% from the December 15th total of 67,700 shares. Based on an average daily trading volume, of 109,400 shares, the short-interest ratio is currently 1.3 days.
View Akari Therapeutics' Short Interest

When is Akari Therapeutics' next earnings date?

Akari Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, April 19th 2022.
View our earnings forecast for Akari Therapeutics

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics, Plc (NASDAQ:AKTX) released its earnings results on Friday, December, 3rd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter.
View Akari Therapeutics' earnings history

Who are Akari Therapeutics' key executives?

Akari Therapeutics' management team includes the following people:
  • Clive Stuart Richardson, CEO, Chief Operating Officer & Director
  • Torsten Hombeck, Chief Financial & Accounting Officer
  • Miles Nunn, Chief Scientific Officer
  • Wynne Weston-Davies, Medical Director

What other stocks do shareholders of Akari Therapeutics own?

What is Akari Therapeutics' stock symbol?

Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."

How do I buy shares of Akari Therapeutics?

Shares of AKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akari Therapeutics' stock price today?

One share of AKTX stock can currently be purchased for approximately $1.43.

How much money does Akari Therapeutics make?

Akari Therapeutics has a market capitalization of $74.23 million. The biopharmaceutical company earns $-17.08 million in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does Akari Therapeutics have?

Akari Therapeutics employs 2,020 workers across the globe.

What is Akari Therapeutics' official website?

The official website for Akari Therapeutics is www.akaritx.com.

Where are Akari Therapeutics' headquarters?

Akari Therapeutics is headquartered at 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT.

How can I contact Akari Therapeutics?

Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The biopharmaceutical company can be reached via phone at 442080040261, via email at [email protected], or via fax at 646-843-9352.

This page was last updated on 1/20/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.